Comorbid patient with osteoporosis at doctor's appointment. What factors should be considered in selection of therapy

Relevance. Osteoporosis is a systemic disease of the skeleton, which is characterized by a decrease in bone mass per unit volume and a violation of the microarchitectonics of bone tissue, which leads to an increase in bone fragility and an increased risk of fractures.

Target. The problems of comorbidity of osteoporosis and polypharmacy in the treatment of this disease are considered.

Materials and methods. On the basis of the Center for Osteoporosis of the Penza Institute for Postgraduate Medical Education, a branch of the Russian Medical Academy of Continuing Postgraduate Education of Russia, we conducted an open, prospective, randomized study of the comorbid status of age-related patients with osteoporosis in order to improve the diagnosis and pathogenetic therapy of the disease. More than 1400 women took part in the study.The results of a study of the comorbid status of age-related patients with osteoporosis are presented. The expediency of antiresorptive therapy in comorbid patients with osteoporosis is discussed.

Conclusions. The characteristics of osteoprotectors of a new generation based on the bioactive component of gonadotropic action are given, and the prospects of these agents in the implementation of a personalized approach in the treatment of osteoporosis, taking into account comorbidity and polypharmacy, are evaluated. Particular attention is paid to the problem of osteosarcopenia and its solution with the help of these osteoprotectors.

1. Pavlova T., Bashuk I. Clinical and morphological features of degenerative changes in bone tissue against the background of osteoporosis in the age aspect. Doctor. 2019. No. 30 (6). P. 47–50.

2. Strukov V., Elistratov D., Kislov A. et al. Osteoporosis in geriatric practice. Doctor. 2018. No. 29 (6). P. 26–30.

3. Dedov D.V. The risk of atrial fibrillation recurrence in patients with coronary heart disease and arterial hypertension according to Holter monitoring of the electrocardiogram. Bulletin of Arrhythmology. 2010. No. 59. P. 27–32.

4. Vertkin A. L., Rumyantsev M.A., Skotnikov A. S. Comorbidity in clinical practice. Archive of Internal Medicine. 2011. No. 2. P. 20–24.

5. Puzyrev V.P. Genetic basis of comorbidity in humans. Genetics. 2015. V. 51, No. 4. P. 491–502.

6. Anosova E., Filimonov M., Proschaev K., Romanchikov A. Polymorbidity – polypharmacy – deprescribing: Current trends in pharmacotherapy of geriatric patients and its optimization. Doctor. 2019. No. 6. P. 17–23.

7. Lubenets A. Treatment of injuries of the proximal femur in patients of the older age group. Doctor. 2017. No. 7. P. 65–67.

8. Clinical guidelines ‘Osteoporosis’. Approved by the Ministry of Health of Russia, 2021. 82 p.

9. Dedov D.V. Osteoporosis in elderly patients: prevalence, pathogenesis, clinic, prevention of complications. Doctor. 2021. No. 32 (7). P. 82–85.

10. Oganov R.G., Denisov I.N., Simanenkov V. T. et al. Comorbid pathology in clinical practice. Clinical guidelines. Cardiovascular therapy and prevention. 2017. Vol. 16 (6). P. 5–56.

11. Strukov V.I., Elistratov D.G., Maksimova M.N., Radchenko L.G., Astafieva A.N., Vikhrev D.V., Alekseeva N. Yu. An interdisciplinary view of the problem of comorbid osteoporosis in the elderly. Nurse. 2022. V. 24, No. 7. P. 3–9.

12. Osadchy A., Zelter P. Dual-energy X-ray absorptiometry in evaluating the effectiveness of osteopenia treatment. Doctor. 2015. No. 11. P. 79–80.

13. Krum S.A. Direct transcriptional targets of sex steroid hormones in bone. J. Cell. Biochem. 2011. V. 112 (2). P. 401–408.

14. Povoroznyuk V.V., Grigorieva N.V. Menopause and osteoporosis. Reproductive Endocrinology. 2012. No. 2. P. 40–47.

15. Yarikov A.V., Smirnov I.I., Pavlinov S.E. Osteoporosis of the spine: Epidemiology, modern methods of diagnosis and principles of treatment. Doctor. 2020. No. 31 (11). P. 21–28.

16. Shishkova V.N., Kosmatova O.V., Skripnikova I.A. Actual issues of diagnostics and therapy of osteoporosis in the practice of a therapist. Medical business. 2021. No. 1. P. 52–61.

17. Strukov V., Elistratov D., Balykova L et al. Effect of Osteomed Forte on hormonal status and course of osteoporosis in postmenopausal women with androgen deficiency. Doctor. 2015. No. (3). P. 28–32.

18. Jones O., Strukov V. et al. Comorbid osteoporosis: Problems and new possibilities of therapy. Doctor. 2017. No. 10. C. 23–26; No. 11, P. 25–28.

19. Munoz E., Rosner F., Friedman R. et al. Financial risk, hospital cost, complications and comorbidities in medical non-complications and comorbidity-stratified diagnosis-related groups. Am. J. Med. 1988. V. 84 (5). P. 933.

20. Vasilenko Yu.K., Klimova O.V., Lazaryan D.S. Biological properties of drone brood under conditions of prolonged hyperlipidemia. Chemical Pharmaceutical Journal. 2002. V. 36, No. 8. P. 34–36.

21. Krylov V.N., Agafonov A.V., Krivtsov N.I., Lebedev V.I., Burmistrova L.A., Oshevensky L.V. etc. Theory and means of apitherapy. Moscow: Research Institute of Beekeeping of the Russian Agricultural Academy, 2007.

22. Vasilenko Yu.K., Klishina I.I., Lazaryan D.S. Comparative study of the immuno- and hepatotropic effects of bee products in rats with chemical intoxication. Chemical Pharmaceutical Journal. 2005. V. 39, No. 6. P. 36–38.

23. Sawczuk R., Karpinska J., Miltyk W. What do we know and what we would like to know about drone homogenate. J. Ethnopharmacol. 2019. V. 245. Article ID111581.

24. Isidorov V.A., Bakier S., Stocki M. GC–MS investigation of the chemical composition of honey bee drone and queen larva homogenate. J. Apic. Sci. 2016. V. 60 (1). P. 33–38.

25. Burmistrova L.A. Physico-chemical analysis and biochemical assessment of the biological activity of drone brood: Dissertation for the degree of PhD of biological sciences: 03.00.04. Ryazan, Russia, 1999. 172 p.

26. Strukov V.I., Elistratov D.G., Strukova-Jones O.V., Eremina N.V., Kuptsova T.A. Problems of diagnostics and therapy of comorbid osteoporosis. Actual issues of diagnostics, treatment and rehabilitation of patients: Materials of the 19th anniversary Interregional Scientific and Practical Conference dedicated to the 40th anniversary of Penza Institute for Postgraduate Medicine – a Branch of Russian Medical Academy for Continuing Professional Education (Penza, Russia). 2017, P. 427–432.

27. Grebennikova T.A., Tsoriev T.T., Vorobieva Yu.R., Belaya Zh.E. Osteosarcopenia: pathogenesis, diagnosis and treatment options. Annals of the Russian Academy of Medical Sciences. 2020. V. 75 (3). P. 240–249.

28. Marchenkova L.A., Makarova E.V. Possibilities of correcting violations of conditional and coordination motor abilities in osteosarcopenia using food supplements with calcium and vitamins D 3 and B6. Doctor. 2020. No. 7. P. 61–68.

29. Marchenkova L.A. Rehabilitation of patients with fractures due to osteoporosis: Questions and answers. Opinion Leader. 2020. No. 5 (34). P. 44–56.

30. Marchenkova L.A., Makarova E.V., Vasilyeva V.A. Effects of basic therapy with calcium and vitamins D3 and B6 on muscle strength, movement and balance functions in patients with osteoporosis undergoing medical rehabilitation. Issues of balneology, physiotherapy and therapeutic physical culture. 2020. No. 97 (1). P. 25–34.